Amplify ETF Trust has decided to terminate and liquidate its Amplify Weight Loss Drug & Treatment ETF. This significant move was made by the Board of Trustees on November 10, 2026, and is set to take effect after the close of business on November 26, 2026. This liquidation is notable as it reflects the ongoing challenges faced by niche ETFs in the investment market.

Amplify ETF Trust, based in Lisle, Illinois, is an investment entity that focuses on exchange-traded funds (ETFs). The Trust has been active in the market with various filings, including a recent series of updates to its prospectus and other regulatory documents. The Amplify Weight Loss Drug & Treatment ETF, which is the subject of this liquidation, was designed to invest in companies involved in weight loss treatments and related healthcare innovations.

According to the filing, the Fund will stop accepting creation orders after November 26, 2026, and trading in its shares will be halted after market close on December 3, 2026. Proceeds from the liquidation are expected to be distributed to shareholders around December 8, 2026. The filing states, "After the close of business on November 26, 2026, subject to applicable law, the Fund will no longer accept creation orders." This indicates a clear timeline for the wind-down process.

The termination of the Fund may affect shareholders who have invested in the ETF, as they will need to make decisions regarding their holdings. They can sell their shares on NYSE Arca until December 3, 2026, and will incur typical transaction fees from their broker-dealers. Post-liquidation, shares will be redeemed for cash at the net asset value on that date. The filing notes that shareholders generally recognize a capital gain or loss on these redemptions.

As the ETF landscape continues to evolve, this decision by Amplify ETF Trust underscores the difficulties that specialized funds may encounter in attracting and retaining investor interest. The filing does not specify what happens next beyond the liquidation process, leaving stakeholders to consider the implications of this move.